Taiho TAS0612-101
Research type
Research Study
Full title
A Phase 1 Study of TAS0612 in Patients with Locally Advanced or Metastatic Solid Tumors.
IRAS ID
308883
Contact name
Jill Kremer
Contact email
Sponsor organisation
Taiho Oncology, Inc.
Eudract number
2020-002304-39
Clinicaltrials.gov Identifier
Clinicaltrials.gov Identifier
149137, IND Number
Duration of Study in the UK
2 years, 2 months, 1 days
Research summary
This is a clinical research trial of TAS0612, which is a drug under investigation. This means that TAS0612 has not been approved for use in the UK and/or for use in subjects with locally advanced or metastatic solid tumors, except in a clinical research trial.
TAS0612 is a research drug that blocks kinases. Kinases are parts of a cell that help it grow, and TAS0612 mostly blocks 3 kinases named RSK, AKT and S6K. Some cancers may grow because RSK, AKT and S6K are not acting normally. TAS0612 may be able to stop cancer growth by blocking RSK, AKT and S6K.
The main purpose of the trial is to find the maximum tolerated dose (MTD), the recommended phase 2 dose (RP2D), and to study the efficacy of TAS0612. The MTD is the highest and safest dose to give subjects. The RP2D is the dose that will be used in subjects that is the safest and has the best chance at shrinking cancer tumors. Efficacy is studying if TAS0612 can stop or shrink the tumor.
REC name
North East - Newcastle & North Tyneside 2 Research Ethics Committee
REC reference
22/NE/0049
Date of REC Opinion
28 Apr 2022
REC opinion
Further Information Favourable Opinion